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Abstract 
Objectives. Examine if aortic valve opening (AVO) and other echocardiographic parameters influence 
outcomes in patients on left ventricular assist device (LVAD) support. 
Background. Pump thrombosis (PT) and ischaemic stroke (IS) are known complications of LVAD, but 
mechanisms that could influence them are not completely understood. 
Methods: Retrospective analysis of 147 patients that received a HeartWare HVAD® as bridge to 
transplant or to candidacy between July 2009 and August 2015, of whom 126 had at least 30 days 
follow-up before first event (“30 days out” cohort). Outcomes included survival, PT, IS and combined 
thrombotic event (PT+IS=CTE).  
Results: Median time on support was 518 days. Of the “30 days out” cohort, 29% had a first PT, and 
19% IS. AVO was associated with longer survival on device (1081 vs 723 days; p=0.01) in the whole 
cohort. In the “30 days out” cohort, AV was more frequently closed in patients with lower ejection 
fractions on support (14±6% vs 18±9%; p=0.009), more dilated pre-event echocardiogram (LV end-
diastolic diameter (LVEDD): 66±12mm vs 62±10mm; p=0.04) and pre-implant LVEDD (70±10mm vs 
66±9mm; p=0.06). CTE-free survival on the device was lower with a closed aortic valve (897 vs 1314 
days; p=0.003) as well as PT-free survival on the device (1070 vs 1457 days; p=0.02). Cox regression 
analysis showed that AVO was an independent predictor of CTE (p=0.03) 
Conclusions: Thrombotic events are relatively frequent in patients on long term LVAD support. A 
closed aortic valve was associated with decreased overall survival, thrombosis-free survival, and 
poorer left ventricular function on support. These are high risk patients so whether they require more 
intense anticoagulation or prioritising for transplantation requires further research. 
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Abbreviations: 
PT. Pump thrombosis 
LVAD. Left ventricular assist device 
IS. Ischaemic stroke 
TIA. Transient Ischaemic Attack 
AVO. Aortic valve opening 
CTE. Combined thrombotic event 
LDH. Lactate dehydrogenase  
LVEDD. Left ventricular end diastolic dimension 
LVDDI. Left ventricular dimension decrement index 
LVEF. Left ventricular ejection fraction 
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Introduction 
Despite improvements in technology with newer generation devices and refinement of anticoagulation 
protocols, pump thrombosis (PT) is a relatively frequent complication of left ventricular assist devices 
(LVAD). It is a serious and potentially life threatening event, with mortality rates reported as high as 
20% at 30 days with the HeartMate II device (1). In the ADVANCE trial of the HeartWare (HVAD) 
device (2) an incidence of 0.08 cases/patient/year was reported, though no increase in mortality. 
These discrepancies in mortality rates may in part be due to difficulties in diagnosing or defining PT, 
so there are concerns about some reports underestimating PT (3) (4). Ischemic stroke (IS) or 
transient ischemic attack (TIA) due to cardioembolism are also important thrombotic complications of 
LVAD support, due to thrombus formation within the left ventricle or the LVAD (5). Incidence was 
reported recently as 1.61 stroke events/100 patients within the first year after implantation (6). A 
number of reasons have been reported as potential factors increasing risk of PT and IS or TIA: 
including lower aspirin dose, low INR or high blood pressure (7).  
 
With limitations in numbers of heart transplantation (8), patients are inevitably supported for longer 
durations with LVADs. This leads to increased exposure to risks of these devices, such as thrombotic 
events. In that respect, the role of aortic valve opening (AVO) and risk of adverse events is not 
known. Potentially some residual AVO may allow washout of blood from the left ventricle that is not 
adequately drained by the LVAD, preventing in-situ left ventricular thrombus formation. However, in 
some cases when the left ventricular function is very poor it may not be possible to preserve any 
AVO. In this report we focus on the echocardiographic parameters that could influence these 
thrombotic events.  
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Methods  
This is a retrospective analysis of patients over 16 years of age that received a HeartWare LVAD 
(HVAD®, HeartWare Inc, Framingham, MA, United States) as bridge to transplant or bridge to 
candidacy in the Freeman Hospital, between July 2009 and August 2015, following the standard 
technique previously described (9). Anticoagulation and antiplatelet regimes have previously been 
described (4), and in brief have been since 2011 a target INR of 2.7 and aspirin 300 mg daily. Before 
that the standard dose of aspirin was 75 mg daily. Patient characteristics and comorbidities as well as 
incidence of events were described using the Freeman Cardiothoracic Transplant database and 
electronic health records. This study adhered to the terms of the United Kingdom Data and Protection 
Act and Freedom of Information Act, and was approved to obtain confidential information by the local 
Caldicott Guardian. 
 
Thrombotic Events: We defined an event as the definitive diagnosis of first episode of PT, IS or TIA. 
We included only first events in the analysis as second and subsequent events could be related to the 
source of the first event, such as a partially resolved PT. We created a first “combined thrombotic 
event” (CTE) that was the sum of the first PT, IS or TIA.  Thus, if a patient had a PT initially and then 
at a later date an IS, only the PT was accounted for in the CTE, and if a patient had a IS initially and 
then at a later date an PT, only the IS was accounted for in the CTE. From these definitions we were 
able to analyse time to first thrombotic event. PT was defined as the presence of one or more of the 
following parameters: persistent increase of pump wattage at rest, significant increase of LDH, need 
for thrombolysis, or pump exchange that revealed evidence of thrombus within the inflow cannula or 
outflow graft. We also included patients with a low wattage, low flow state (without any other 
explanation such as dehydration, bleeding, right ventricular failure or high afterload), that resolved 
after thrombolysis or underwent pump exchange that revealed evidence of thrombus within the inflow 
cannula or outflow graft. IS and TIA were diagnosed clinically with appropriate imaging. We excluded 
intracranial bleeding that was suspicious of a primary cardioembolic event with secondary 
haemorrhagic transformation, as this is difficult to diagnose with certainty.  
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Echocardiography: Transthoracic echocardiograms were performed as clinically indicated by 
experienced sonographers using both Philips (Koninklijke Philips, Andover, MA, United States) and 
General Electric (General Electric Company, Fairfield, CT, United States) devices. Echocardiograms 
were reviewed twice by a cardiologist with specialist training in echocardiography. Pre-implant 
echocardiograms were reviewed and left ventricular end diastolic dimension (LVEDD) measured. We 
reviewed the last echocardiogram available for each patient if they did not have any thrombotic event, 
which if the patient is still alive would be the most recently available or if deceased, the last prior to 
death. In patients with one of the defined thrombotic events, the last pre-event echocardiogram was 
reviewed. If this was performed more than 3 months before the event, it was compared with the one 
performed when the thrombotic event was resolved to establish if this was a representative current 
assessment of the left ventricle and aortic valve.  Echocardiograms performed during the acute phase 
of a PT were not included as LVEDD and aortic valve opening (AVO) can be affected by the presence 
of a thrombus. LVEDD, visual estimate of left ventricular ejection fraction (LVEF) and aortic valve 
opening (AVO) were the variables analysed in the pre-event echocardiogram. LVEF was quantified by 
visual estimate due to difficulties in using standard measurement methods in this population (10).  
LVEDD percentage change or left ventricular dimension decrement index was calculated (LVDDI; 
preoperative end-diastolic dimension – subsequent echocardiogram end-diastolic dimension divided 
by preoperative dimension x100) adapted from a recent description (11).  
 
Aortic Valve Opening: We created 2 categories for the AVO variable, “Yes” or “No”.  This required 
careful categorization.  AVO was defined as “Yes” when it opened completely or partially in every 
cardiac cycle or just sometimes but on a regular basis and “frequently”. “Frequently” was a subjective 
measurement, but for example included those in which the aortic valve opened every third or fourth 
cardiac cycle. There were a small number of cases in which aortic valve opened less frequently, but 
nevertheless not so infrequent to be considered closed. In this situation, subsequent 
echocardiograms in the following weeks or few months were reviewed to check if the trend was to 
open on a regular basis or the opposite, to define “Yes” or “No“ AVO status. AVO was considered 
closed when it was completely and always closed or when opening was only very occasional or the 
leaflets moved only slightly without effective transvalvular flow. 
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Pump speed: Pump speed (rpm; revolutions per minute) was set at the time of implantation to 
achieve an optimal position of the intraventricular septum, with if possible, some residual AVO. Pump 
speed was not routinely changed post implant. 
 
Right Heart Catheter. We included haemodynamic data of the first right heart catheterization 
performed after discharge from the HVAD implantation. 
 
Cohorts of analysis. We analysed the outcomes of the whole cohort but also created a sub-cohort 
with at least 30 days of follow-up before a first event. This ’30 days out’ cohort excluded those 
patients that died within 30 days of implant, had less than 30 days follow up at the time of analysis 
(recent implants), and had a thrombotic event before 30 days (as this was felt to represent a different 
mechanism to later thrombotic events). For these reasons, we concentrated on the “30 days out” 
cohort in the analysis of thrombotic events. 
 
Data and statistical analysis: Data are presented as mean ± standard deviation (SD) and duration 
of days as median and mean. Outcome measures used were all-cause mortality and survival on the 
device using Kaplan–Meier survival curves, comparing above and below mean values for each 
variable, and the log-rank test for significance. Single unpaired comparisons were made with Student 
T-test or the Mann–Whitney U-test when data was not normally distributed. We used the Cox 
proportional hazard model for multivariate analysis. P<0.05 was considered significant. The statistical 
software used for analyses was SPSS Statistics Version 20. 
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Results 
147 patients were implanted during the study period and 126 of them had at least 30 days of follow up 
before a first event.  The aortic valve was closed in 39.3% of the patients of the full cohort and in 
37.1% of the “30 days out” cohort. Mortality at 30 days was 12.2%. 4 patients had aortic valve 
replacement (AVR) at the time of the HVAD implant and 2 more patients had previous AVR. No 
cannula malposition was found. Of the 126 patients with at least 30 days of follow-up until a first 
event, 36 (28.6%) had an episode of first PT, 24 had an episode of first IS (19%) and 50 patients had 
one episode of PT, IS or both (39.7%). Mean time on HVAD support was 657±510 days, with a 
median of 518 days. This results in a risk of 0.15 cases of first PT/patient/year and a risk of 0.22 
cases of first CTE/patient/year. Median time to post-implant right heart catheterization was 231 days. 
 
Lack of Reverse Remodelling on Device is Associated with Thrombotic Events: Characteristics 
of patients that had a PT, IS and CTE are shown in tables 1, 2 and . Duration of support until the 
development of a thrombotic event was by median over 1 year, and for PT 13 months. There was no 
impact on overall survival on the device with Kaplan-Meier analysis (mean, days, with or without PT, 
IS and CTE, 1058±107 vs 1000±87, p=0.88; 922±124 vs 1050±84, p=0.69 and 1010±93 vs 1036±99, 
p=0.75, respectively). Mortality at 30 days post CTE was 10%. There were no differences in the 
number thrombotic events by aspirin dosage, but the number of patients on low dose aspirin was 
small (13.5% on 75 mg, 4% without aspirin or any other antiplatelet and 9.5% on clopidogrel 
monotherapy). Patients that had PT showed greater LVEDD post implant (66.1±12.2 mm vs 62.0±9.8 
mm; p=0.05), smaller LVDDI (-2.57±10.84% vs -7.60±9.77%; p=0.01) and lower mixed venous 
oxygen saturation (61.2% vs 64.9%; p=0.05). Patients that had CTE showed smaller LVDDI (-
3.11±10.4% vs -8.18±10.04; p=0.009) 
 
Aortic Valve Opening is Associated with Better Survival, Less Thrombotic Events, and Better 
Preserved LV Function: “30 days out” cohort AVO characteristics are shown in table 4. Aortic valve 
was more frequently closed in patients that had the CTE (50% vs 28.4%%; p=0.014). In 7 patients of 
the whole cohort (4.7%) it was not possible to assess AVO as most of these patients died in the first 
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2-3 days after the implant without adequate imaging. AVO was associated with longer survival on 
device (Kaplan-Meier analysis: mean, days, 1081±96 vs 723±89; p=0.01, figure 1A) in the whole 
cohort of 147 patients and a trend towards longer survival in the patients with at least 30 days follow-
up before any event (mean, days, 1152±99 vs 862±94; p=0.08, figure 1B). CTE-free survival on the 
device was significantly lower in patients with a closed aortic valve (mean, days, 897±87 vs 
1314±103; p=0.003, figure 2A) as well as PT-free survival on the device (mean, days, 1070±102 vs 
1457±108; p=0.02, figure 2B). Patients in whom the aortic valve was closed had lower ejection 
fractions on support (14±6% vs 18±9%; p=0.009), more dilated pre-adverse event echocardiogram 
(LVEDD): 66±12 mm vs 62±10 mm; p=0.04) and pre-implant LVEDD (70±10 mm vs 66±9 mm; 
p=0.06). Pump speeds were not related to a closed aortic valve (2555±154 rpm closed aortic valve vs 
2604±199 rpm open aortic valve; p=0.24), but lower cardiac output (4.3±0.9 closed aortic valve vs 
4.7±0.9 open aortic valve; p=0.06) and lower mixed venous saturation were (61.2±6.4% vs 
65.3±7.7%; p=0.02). A closed aortic valve was not significantly related to shorter time to death on the 
device in patients that had a CTE and died (307 days with a closed aortic valve vs 363 days with an 
open aortic valve, p=0.66), but numbers in comparison were small (N = 17 vs 15 respectively). In the 
Cox regression survival model that included AVO, LVDDI, sex, atrial fibrillation, age at implant and 
LVEF, a closed AV was an independent factor that increased the risk of having a CTE (hazard ratio 
2.05 95% IC 1.07-3.94; p=0.03).  
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Discussion 
In this single centre study of 126 HVAD patients with a median of over 500 days follow up, we show 
that a closed aortic valve was strongly related to adverse outcomes, including CTE-free survival and 
PT-free survival, as well as increased mortality. Furthermore, less reverse remodelling on support 
with reduced LVDDI was also related to PT and CTE, and greater LVEDD on support was also 
associated with increased rates of PT.  
Reverse remodelling: Joyce and colleagues have recently described in 64 subjects with the 
Heartmate II device, that less reverse remodelling of the left ventricle on support was associated with 
greater risk of pump thrombosis (11). Comparisons between the current study and Joyce et al are 
difficult. Nevertheless, with respect to reverse remodelling, we also show that greater reductions in left 
ventricular size are associated with less adverse events. In that study, the Heartmate II device was 
used, which has several fundamental differences to the HVAD. Our median time to PT was 13 
compared to 8 months, and the protocol for setting pump speeds different. Their incidence of pump 
thrombosis was 0.06 per patient year compared to our higher rate of 0.15. They performed a pre-
discharge ramp test, whereas our pump speeds were set at the time of LVAD implant. Also, in that 
series more than 70% had a closed aortic valve compared with less than 40% in the present study.   
There are several potential explanations for the higher PT rates in the current study. Compared to 
other series there is a longer duration of support (11) (12), which can at least partially explain higher 
thrombotic event rates (as these are related to the duration of support (4)). This is also supported by 
the fact that our median time to PT is longer than other series (11). A unique aspect of our study 
population are the relatively low rates of transplantation in a group of patients in whom the indications 
were bridge to transplant or bridge to decision (8). In the ADVANCE trial the rates of transplantation at 
6 months were almost 30% (16), so in that situation, those with potentially life threatening 
complications on support can receive the bail-out option of a transplant. Our rates of transplantation 
are much lower (4), with only 4% receiving a transplant at 6 months post implant, so those that 
developed serious adverse events such as PT, IS or CTE remained at risk for further subsequent 
events and death. It is also quite possible that some series are underestimating the true PT 
occurrence for several reasons (3)  
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Aortic Valve Opening: Mechanisms and Significance: Our findings with respect to AVO are quite 
novel, though the mechanism of these findings are not certain. Thrombus formation on the aortic 
valve and in the left ventricular outflow tract in closed aortic valves have been described in the 
literature (13) (14), so this could be a source of thrombus to subsequently migrate through the device 
causing a PT. We cannot definitively state that all patients with a HVAD should have pump speeds set 
so that there is AVO. A closed aortic valve is not only a reflection of pump speed, but also right heart 
function, afterload and intrinsic left ventricular contractility, so those patients who have less AVO in 
this series maybe more intrinsically at higher risk for adverse outcomes. This contention is supported 
by the lower ejection fractions and cardiac output in those without AVO, and that pump speeds were 
not significantly different between the 2 groups. Whether this means that higher pump speeds with a 
theoretical objective of more left ventricular unloading would improve outcomes, or alternatively just 
shows that patients with better preserved intrinsic right and left ventricular function have more AVO 
and therefore less thrombotic adverse events is not known. The most logical way to address this 
issue would be a randomized controlled trial comparing different pump speed strategies and 
outcomes Nevertheless, our data show that patients without AVO are at high risk for events and so 
may benefit from more intense anticoagulation and should even be considered for prioritization for 
transplantation 
 
One aspect of our study population is the relatively high levels of AVO as detailed above (8), and also 
lower pump speeds than previously reported (9).  We have previously reported the hemodynamic 
effects of the HVAD in a smaller cohort of patients (15). At 200 days of support we reported that the 
left ventricular end-diastolic dimension reduces from 7.2±1.0 to 6.9±1.2 cm (at an average of 
2522±174 rpm). In contrast, Gupta et al (12) have shown with their cohort of HVAD patients that at 
100 days left ventricular end-diastolic dimension reduces from 7.1±1.3 to 6.1±1.4 cm, though at a 
higher mean pump speed of 2693±139 rpm, specifically set so that the aortic valve was closed. Thus, 
our relatively low pump speed settings, and therefore higher rates of AVO, may directly affect our 
ability to detect these differences in outcomes. Regarding other echocardiographic parameters, we 
have recently shown that significant aortic regurgitation is very rare and so have not to included this in 
this analysis  (16). 
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Limitations: This is a retrospective study so data was not obtained at pre-specified times. The AVO 
categories of “Yes” or “No” could be subjective in some cases. Analysis of left ventricular function post 
device insertion is difficult due to the presence of the device, and we do not have data on right 
ventricular function that might have influenced AVO. This is a single centre study, with potentially 
some unique characteristics such as relatively low pump speeds and low rates of transplantation, so it 
will be necessary to replicate this study in other centres. Most importantly, a prospective study of 
setting pump speeds to allow or prevent AVO is warranted to define the optimal settings for these 
devices, which appears particularly important as duration of support inevitably increases. 
Furthermore, in groups of patients with whom AVO is not possible, who seem at higher risk of 
thrombotic events, further study is needed to determine whether they should receive more intense 
anticoagulation or antiplatelet therapies.  
 
Conclusions 
Despite improvements in technology and anticoagulation protocols, thrombotic events are still 
relatively frequent in patients that receive a HVAD device, although they are not related to increased 
mortality. A closed aortic valve is associated with decreased overall survival, thrombosis-free survival, 
and poorer left ventricular function on support. These are high risk patients so whether they require 
more intense anticoagulation or prioritising for transplantation requires further research.  
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Table 1 Pump 
Thrombosis 
(36) 
No Pump 
Thrombosis 
(90) 
Significance 
Age 46.79±12.7 47.29±12.7 0.84 
Gender (male) 80.6% (29) 87.8% (79) 0.29 
INTERMACS 
            1 
            2 
            3 
            4 
 
2.8% (1) 
33.3% (12) 
19.4% (7) 
44.4% (16) 
 
6.7% (6) 
27.8% (25) 
33.3% (30) 
32.2% (29) 
 
 
0.29 
Diagnosis 
            DCM 
            IHD 
            CHD 
            Others 
 
44.4% (16) 
50% (18) 
2.8% (1) 
2.8% (1) 
 
 
51.1% (46) 
34.4% (31) 
10% (9) 
4.4% (4) 
 
0.36 
Atrial Fibrillation 22.9% (8) 31.8% (27) 0.32 
Transplant 22.2% (8) 12.2% (11) 0.15 
Decommission or explant 13.9% (5) 7.8% (7) 0.29 
Pump speed (rpm) 2523±146.7 2603±192.4 0.15 
Support until event (median, days) 423 (178-620) 383 (179-742) 0.81 
Aspirin 150 mg or more 
 
69.4% (25) 72.2% (65) 0.75 
LVEF  15.97±7.4 16.99±8.6 0.53 
LVEDD baseline 67.88±9.7 67.52±9.1 0.84 
LVEDD  66.14±12.1 62.04±9.8 0.05 
LVDD Index (%) -2.57±10.8 -7.60±9.7 0.01 
RA pressure 8.00±6.18 7.00±5.77 0.48 
Mean Pulmonary Pressure 22.12±8.22 22.33±9.40 0.92 
Cardiac Output 4.51±0.84 4.56±0.96 0.82 
mVO2 61.29±6.52 64.91±7.71 0.05 
No AVO 47.2% (17) 33.0% (29) 0.13 
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Table 2 Ischaemic Stroke or 
TIA 
(24) 
No Ischaemic 
Stroke or TIA 
(102) 
Significance 
Age 47.96±10.5 46.95±13.2 0.72 
Gender (male) 83.3% (20) 86.3% (88) 0.71 
INTERMACS 
            1 
            2 
            3 
            4 
 
0% (0) 
20.8% (5) 
20.8% (5) 
58.3% (14) 
 
6.9% (7) 
31.4% (32) 
31.4% (32) 
30.4% (31) 
 
0.06 
Diagnosis 
            DCM 
            IHD 
            CHD 
            Others 
 
58.3% (14) 
25% (6) 
8.3% (2) 
8.4% (2) 
 
47.1% (48) 
42.2% 43 
7.8% (8) 
3% (3) 
 
0.46 
Atrial Fibrillation 37.5% (9) 27.1% (26) 0.31 
Transplant 25% (6) 12.7% (13) 0.13 
Decommission or explant 4.2% (1) 10.8% (11) 0.32 
Pump speed (rpm) 2569±143 2587±192 0.74 
Support until event 
(median, days) 
358 (165-557) 403 (184-757) 0.29 
Aspirin 150 mg or more 
 
70.8% (17) 71.6% (73) 0.94 
LVEF  17.08±5.9 16.60±8.8 0.79 
LVEDD baseline 67.05±7.6 67.76±9.6 0.74 
LVEDD  62.35±7.2 63.40±11.3 0.67 
LVDD Index (%) -5.84±8.6 -6.21±10.7 0.88 
RA	pressure 9.13±7.58 6.87±5.34 0.17 
Mean	Pulmonary	Pressure 21.69±6.86 22.40±9.48 0.77 
Cardiac	Output 4.28±0.66 4.61±0.96 0.22 
mVO2 63.62±6.88 63.71±7.67 0.96 
No AVO 50.0% (12) 34.0% (34) 0.14 
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Table 3 Combined Event 
(50) 
No Combined 
Event (76) 
Significance 
Age 46.14±12.2 47.81±13.0 0.47 
Gender (male) 80% (40)  89.5% (68) 0.13 
INTERMACS 
            1 
            2 
            3 
            4 
 
2% (1) 
32% (16) 
22% (11) 
44% (22) 
 
7.9% (6) 
27.6% (21) 
34.2% (26) 
30.3% (23) 
 
0.15 
Diagnosis 
            DCM 
            IHD 
            CHD 
            Others 
 
54% (27) 
36% (18) 
4% (2) 
6% (3) 
 
46.1% (35) 
40.8% (31) 
10.5% (8) 
2.6% (2) 
 
 
0.52 
Atrial Fibrillation 22.4% (11) 33.8% (24) 0.18 
Transplant 22% (11) 10.5% (8) 0.07 
Decommission or explant 10.% (5) 9.2% (7) 0.88 
Pump speed (rpm) 2543±149 2603±198 0.17 
Support until event (median, 
days) 
406 (165-670) 383 (201-805) 0.62 
Aspirin 150 mg or more 
 
68% (34) 73.7% (56) 0.49 
LVEF  15.90±6.9 17.23±9.1 0.38 
LVEDD baseline 67.00±9.3 68.04±9.3 0.55 
LVEDD  64.65±11.4 62.25±10.1 0.22 
LVDD Index (%) -3.11±10.1 -8.17±10.1 0.009 
RA pressure 8.41±6.62 6.49±5.16 0.15 
Mean Pulmonary Pressure 22.00±7.56 22.45±10.01 0.83 
Cardiac Output 4.47±0.80 4.60±1.00 0.51 
mVO2 62.32±6.68 64.75±7.97 0.17 
No AVO 50% (25) 28.4% (21) 0.01 
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Table 4 AVO 
(78) 
No AVO (46) Significance 
Age 47.17±12.87 46.51±12.42 0.78 
Gender (male) 88.5% (69) 80.4% (37) 0.22 
INTERMACS 
            1 
            2 
            3 
            4 
 
5.1% (4) 
28.2% (22) 
30.8% (24) 
35.9% (28) 
 
3 (6.5%) 
32.6% (15) 
28.3% (13) 
32.6% (15) 
 
0.93 
Diagnosis 
            DCM 
            IHD 
            CHD 
            Others 
 
52.6% (41) 
38.5% (30) 
3.8% (3) 
5.2% (4) 
 
43.5% (20) 
39.1% (18) 
15.2% (7) 
2.2% (1) 
 
0.18 
Atrial Fibrillation 29.3% (22) 27.9% (12) 0.52 
Transplant 10.3 (8) 23.9% (11) 0.04 
Pump speed (rpm) 2604±199 2555±154 0.24 
Support until event (median, 
days) 
403 386 0.43 
Support until event (mean, 
days) 
555±479 457±368 0.23 
LVEF  18.25±9.02 14.24±6.23 0.009 
LVEDD baseline 66.41±8.50 69.67±10.29 0.06 
LVEDD  61.76±9.59 65.73±12.08 0.04 
LVDD Index (%) -6.55±10.78 -5.37±9.63 0.55 
RA pressure 6.79±5.43 8.20±6.55 0.31 
Mean Pulmonary Pressure 21.17±9.03 23.90±8.77 0.19 
Cardiac Output 4.70±0.94 4.31±0.85 0.07 
mVO2 65.33±7.74 61.18±6.42 0.02 
Pump thrombosis 24.4% (19) 37% (17) 0.09 
Ischaemic Stroke / TIA 15.4% (12) 26.1% (12) 0.14 
Combined Event 32.1% (25) 54.3% (25) 0.014 
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